Navigation Links
MedImmune Focused on Revolutionizing Cancer Care
Date:11/16/2010

GAITHERSBURG, Md., Nov. 16, 2010 /PRNewswire/ -- Today, MedImmune announced that researchers will present data from its oncology portfolio, including new clinical data, at two upcoming medical congresses in Europe and the United States.

"At MedImmune, we are thinking about cancer and treatment in new ways, using insights and understanding of the disease to discover breakthrough biologic therapies that can be used to treat specific cancers for the individual patient," said Jerry McMahon, Senior Vice President and Oncology Innovative Medicines Unit Leader.  "We are excited about the progress of the oncology portfolio and are looking forward to its advancement of multiple oncology products into expanded clinical studies in the near future."  

With innovative antibody and biologic technologies, the MedImmune Oncology pipeline is focusing on developing new therapies to eliminate cancer cells in more effective and targeted ways.  This research is addressing the key areas critical to the development and progression of cancer: immune-mediated killing, vascular modulation, growth factor, and survival signaling.  

"The identification of novel cancer drug targets and associated biologic markers has not only altered the way we view cancer, but is truly revolutionizing our standard of care," said Bahija Jallal, Executive Vice President Research and Development at MedImmune.  "It is this research, with products like moxetumomab pasudotox (CAT-8015), that will help develop more effective solutions to targeting malignant tumor cells and providing a more personalized approach to medicine."

New data presentations

Four MedImmune-sponsored posters are being presented at the 22nd EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics" starting on Tuesday, November 16 in Berlin.  EORTC-NCI-AACR is a joint meeting of the European Organisation for Research and Treatment of Cancer, the National Cancer Institute and the American Association for Cancer Research.  These abstracts include:

  • Glioblastoma multiforme is characterized by high incidence of PDGFR-alpha expression and susceptibility to the PDGFR-alpha-specific antibody MEDI-575 in mouse tumor models – presented by Dr. Philipp Steiner, on Wednesday, November 17

  • Inhibition of PDGFR-alpha in tumor stroma with MEDI-575 enhances activity of carboplatin/  paclitaxel and delays tumor regrowth in a NSCLC xenograft model – presented by Dr. Philipp Steiner, on Wednesday, November 17

  • Phase I study of MEDI-575, a fully human monoclonal antibody targeting PDGFR-alpha in subjects with advanced solid tumors – presented by Dr. Robert Lechleider, on Thursday, November 18

  • MEDI-573, a dual IGF-1/-2 neutralizing antibody, blocks IGF-1R and IR-A signaling and maintains glucose homeostasis in a phase 1 study for advanced solid tumors –presented by Dr. Michael Menefee, on Thursday, November 18

Then in December, two MedImmune-sponsored posters are being presented at the 52nd ASH (American Society of Hematology) starting on Saturday, December 4 in Orlando, including:

  • A phase I study of moxetumomab pasudotox (CAT-8015), an anti-CD22 recombinant immunotoxin, in relapsed/ refractory hairy cell leukemia (HCL): updated results – presented by Dr. Robert Kreitman, on Sunday, December 5

  • Complete remissions in 3 of 12 patients with chemotherapy-refractory pediatric acute lymphoblastic leukemia (ALL) during phase I testing of the anti-CD22 immunotoxin moxetumomab pasudotox (CAT-8015)– presented by Dr. Alan Wayne, on Monday, December 6

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MedImmune to Present Five Abstracts on RSV at Pediatric Academic Societies Annual Meeting
2. MedImmune to Present Data on RSV and Influenza at 2009 American Academy of Pediatrics National Conference & Exhibition
3. MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
4. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
5. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
6. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
7. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
8. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
9. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
10. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
11. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016 Transformational M&A achieved through NPS ... --> Transformational M&A achieved through NPS and Dyax ... Transformational M&A achieved through NPS and Dyax acquisitions ... for future growth with most robust pipeline in Shire ... future growth with most robust pipeline in Shire , ...
(Date:2/11/2016)... 11, 2016  AbbVie, a global biopharmaceutical company, ... designed to provide financial support for exceptional students ... higher education goals. Fifteen scholars will be selected ... year. The AbbVie Rheumatology Scholarship is currently accepting ... president, corporate social responsibility, brand and communications, AbbVie. ...
(Date:2/11/2016)... Exactus Pharmacy Solutions, a WellCare (NYSE: ... care for those suffering from long-term, life-threatening or ... Specialty Pharmacy Accreditation from URAC, an independent, nonprofit ... care quality through accreditation, education and measurement. ... URAC accreditation process demonstrates a commitment to quality ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... “ HEALING MIND : Five ... Managed Mind” (published by Balboa Press) teaches readers how to become their own therapist. ... love, author Janice McDermott, M.Ed., LCSW, offers an understanding of how to heal one’s ...
(Date:2/11/2016)... Jersey (PRWEB) , ... February 11, 2016 , ... Registered ... a free CEU seminar titled, “Stroke Management: Time to Act, Time to Heal” on ... Community in Whippany, N.J. The presenter is Vishal Chedda, president of ANSA Consultants, ...
(Date:2/11/2016)... ... February 11, 2016 , ... Image One USA ... new market, and it’s the buildings of Nashville that will benefit. , “I’ve enjoyed ... to relocate to Nashville, there was no question that I would bring my business ...
(Date:2/11/2016)... ... February 11, 2016 , ... Pediatric cardiovascular surgeons, cardiologists ... by making data on heart procedures public and easily understandable for families and ... Reporting of Pediatric and Congenital Heart Disease Outcomes will bring hundreds of pediatric ...
(Date:2/11/2016)... ... February 11, 2016 , ... veEDIS Clinical Systems, ... with highly adaptable algorithms, has been updated to help Emergency Department physicians and ... consistent with Zikas and a travel history to affected regions, or potential exposure ...
Breaking Medicine News(10 mins):